Thoughts on Lilly’s Humalog Authorized Generic

Today, Lilly announced it will commercialize an authorized generic for Humalog U-100 at a 50% discount to the current Humalog per-unit list price for vial and Kwikpen. Nothing was mentioned about Humalog premixes. Below, FENIX provides summary and insight, including Lilly’s potential motivation and why Novo Nordisk is unlikely to follow.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.